ASAH1 and Fabry disease: Remarkably, many other ongoing studies aimed to increase ACDase activity and decrease ceramide levels, as gene therapies using lentiviral or retroviral vectors and enzyme replacement therapy (ERT) with recombinant human ACDase, and are expected to improve life expectancy in FD patients in the future (Pewzner‐Jung et al., 2014; Schuchman et al., 2015).